ONLINE SUBMISSION
  October, 2007

Lumbar Osteomyelitis with Pseudomonas

  Nasim Sabir, Badar Jahan Farooqi  ( Departments of Microbiology, Ziauddin University Karachi. )
Sohail Rafi, Imtiaz Hashmi  ( Departments of Orthopaedics, Ziauddin University Karachi. )
 

Abstract
Osteomyelitis is the inflammation of bone secondary to infection with pyogenic organisms. Pseudomonas aeruginosa is usually associated with nosocomial infections and due to its ability to acquire resistance to almost all antibiotics, infections with Pseudomonas pose a great challenge to the physicians. A number of new synergistic combinations have been used in order to treat these organisms and one of the methods is to combine chemicals with systemic antibiotics. In this case we represent a successful eradication of multidrug resistant Pseudomonas using a combination of acetic acid and systemic antibiotics.

Introduction
Osteomyelitis is an acute or chronic inflammatory process of the bone and its structures secondary to infection with pyogenic organisms.1 There are two known categories, haematogenous and locally contagious. A number immune suppressive conditions including diabetes mellitus make a patient more prone to development of osteomyelitis.1,2.  In addition, the presence of a prosthetic orthopaedic device is an established independent risk factor.2 Pseudomonas aeruginosa has been associated with skin and soft tissues infections particularly seen in cases diabetic foot and post surgical cases associated with prosthetic implants.3
Pseudomonas have been reported to acquire resistance by a number of mechanisms and to almost all currently available drugs, and these pan resistant organisms have been considered as the most difficult to eradicate.4,5 Recently a few strategies have been adopted by applying new combination of chemicals like acetic acid, polyamines and polymixin as adjuvant to systemic antibiotic which have shown favourable results.6-8
In this report a case of suspected osteomyelitis  with pan resistant pseudomonas has been reported where a successful eradication was obtained by a combination of local 1% acetic acid as an adjuvant to systemic antibiotic therapy.

Case Report

A 55 years old diabetic female was admitted at Ziauddin University Hospital, Clifton,
Karachi, with complains of fever and pussy discharge from the surgical wound at the surgery lumbar region operated one year back at our hospital. This patient had a long history of spinal symptoms and had been operated 10 years ago at some other centre for spinal stenosis. No records were available for this surgery.
Her operation at our centre last year was after finding dural compression on MRI scan at the level of L 3-4 vertebrae. A posterior decompression and spinal instrumentation was performed under antibiotic cover and patient was discharged from the hospital after two weeks. As her blood culture revealed E-Coli (Table) she was given 1/V Inj Imipenem and Amikacin for two weeks. Oral ciprofloxacin was advised for six weeks on her discharge from the hospital.

[(0)]

[(1)]

On her current visit she had low-grade intermittent fever, greenish and foul smelling wound discharge. X-rays and MR1 revealed an abscess around the surgical implant. Pus cultures confirmed infection with Enterobacter species, Pseudomonas aeruginosa and Staph aureus (Table). Therefore 1/V Injection Piperacillin Tazobactum (Tzp) was started after wound debridement for two weeks.
As the wound did not show any improvement it was further explored, implant was taken out, pus was drained and again sent for culture. This time culture revealed pure growth of Pseudomonas aeruginosa sensitive to Pipracillin tazobactum (Tzp) and Gentamicin. A combination of both drugs was started; in addition, Oral Ciprofloxacin and Rifampicin were also added.
Despite antibiotics and daily wound cleaning following standard protocol, the pus continued to ooze out of the wound as well as from the screw tracks in the vertebral bodies. Suspecting osteomyelitis, pus culture were sent again, and this time it revealed multi drug resistant Pseudomonas aeruginosa sensitive to Polimixin B (Pb) and Acinobacter lowfii sensitive to Polymixin B and cephoperazone / sulbactam (Sulzone) only.
As published data does not show much evidence in support of the use of Polymixin B as well as citing the toxicity of the drug, a combination of I/V Inj. Sulzone and  dressing the wound with gauze pieces soaked in 1% acetic acid was started and continued for three weeks.
Soakage gradually appeared to diminish and wound started showing good healing. Treatment was continued for total of five weeks and wound was finally closed in two stages. Final cultures yielded no growth. No untoward local or systemic side effects were observed. The patient was finally discharged, and followed up after every three weeks with blood CBC, ESR and CRP reports for the first three months and then followed three monthly. I/V Inj. Sulzone was continued for six weeks after discharge and oral Cefixime was given for the next twelve weeks as we did not want a recurrence of infection.  The patient is still on follow up but has not shown any signs of infection.


Discussion
Pseudomonas aeruginosa has been associated with orthopaedic infections and particularly in those involving implants1,2, and due to its ability to form biofilms it has been one of the most difficult organisms to treat.3,7 The other clinical problem with Pseudomonas infections is the ability of the organism to acquire resistance to almost all the available drugs, whenever confronted with these. A similar situation was faced by the health professionals in this case also as the treatment options were very few, though we didn't have a clear cut diagnosis, but the surgeons were all in favour of Osteomyelitis due to pus oozing out of the screw tracks in the vertebral bodies. On the contrary a good bone healing suggested soft tissue infection rather than osteomyelitis.
Use of acetic acid as adjuvant to systemic antibiotics has been reported in literature mainly in cases of bed sores, deep seated abscesses and diabetic foot ulcers.9 A clear evidence of its use in cases of osteomyelitis could not be found, so it has been tried in osteomyelitis of lumbar vertebrae and resulted in an eradication of the organisms. The role of cephoperazone /sulbactam (Sulzone) could not be established in this case as Pseudomonas was found resistant to the drug, but may be the combination proved synergistic in eradicating the organism.

References
1. Lew DP, Waldvogel FA. Osteomyelitis. N Eng J Med 1997; 336:999-1007.
2. Carek PJ, Dickerson LM, Sack JL. Diagnosis and Management of Osteomyelitis Am Fam Physician. 2001 ;63:2413-20
3. Elliott SJ, Aronoff SC.  Clinical presentation and management of Pseudomonas osteomyelitis. Clin Pediatr. 1985; 24:566-7
4. Aloush V, Navon-Venezia S, Seigman-Igra Y, Cabili S,   Carmeli Y.  Multidrug-Resistant Pseudomonas aeruginosa: Risk Factors and Clinical Impact Antimicrob Agents Chemother 2006; 50: 43-8.
5. Quale J, Bratu S, Gupta J, Landman D. Interplay of efflux system, ampC, and oprD expression in carbapenem resistance of Pseudomonas aeruginosa clinical isolates. Antimicrob Agents Chemother 2006; 50:1633-41.
6. Kwon DH, Lu CD. Polyamines increase antibiotic susceptibility in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2006; 50:1623-7.
7. Banin E, Brady KM, Greenberg EP. Chelator-induced dispersal and killing of Pseudomonas aeruginosa cells in a biofilm. Appl Environ Microbiol 2006; 72:2064-9.
8. Chang W, Small DA, Toghrol F, Bentley WE. Microarray analysis of toxicogenomic effects of peracetic acid on Pseudomonas aeruginosa. Environ Sci Technol 2005; 39:5893-9.
9. Habif TP. Images in clinical medicine. Pseudomonas Cellulitis. N Engl J Med 2005; 14: 353:e2.

News & Events

WHO/GOARN Request for technical assistance for Cholera Control in Northern Iraq

Request for assistance

WHO is requesting assistance from GOARN partners to identify the following cholera and diarrhoeal diseases expertise to support the Ministry of Health of Iraq in cholera risk assessment and immediate preparedness activities to improve the health outcomes of the Syrian refugees current living in camps in the Kurdistan region of Iraq.

  • two (2) epidemiologists
  • two (2) clinical management experts
  • one (1) environmental health expert (WATSAN)
  • one (1)laboratory expert

Duration

6 day mission starting 13 June 2014 (this excludes travel time).

Location

Northern Iraq (Kurdistan region).

Language requirements

All candidates must be fluent in English- written, spoken and comprehension. Fluency in Arabic is an asset. Knowledge, abilities and skills All candidates are expected to demonstrate the following

  • Ability to conceptualize and promote innovative strategies and policies.
  • Ability to communicate and write in a clear concise manner, and to develop effective guidelines.
  • Excellent negotiation and interpersonal skills complemented by ability to motivate and lead others and to promote consensus. Tact, discretion and diplomacy
  • Demonstrated ability for project appraisal, project management, monitoring and evaluation and project impact assessment.
  • Ability to work with host governments and their agents, INGOs and national NGOs an advantage.
  • Proven experience of managing a large workload and multiple priorities.
  • Ability to work in difficult conditions.

Support to the mission

WHO/GOARN will cover the travel and per diem (to cover daily expense in the field) expenses for the duration of their mission. GOARN missions do NOT offer salary, consultancy fees or any other form of remuneration.

WHO will provide appropriate logistics support for the field mission. Pre-deployment orientation/training may be required at WHO.

Partners offers of assistance

Partners are requested to reply with offers of assistance, together with CVs and details of the availability of staff for this mission by email to goarn@who.int latest by 30 May 2014. Details of all offers from partners and eventual deployments will be maintained on the GOARN SharePoint.

Operational Contacts

Mamunur Malik WHO EMRO malikm@who.int

William Perea WHO HQ pereaw@who.int

Patrick Drury GOARN druryp@who.int



News



Index



Supplement